Unscheduled acute care, ED visit, or hospital admission 47 weeks · adults and children with chronic asthma
1 finding from 1 review
Serious adverse events 48 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes serious adverse events 48 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Non‐serious adverse events 43 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes non‐serious adverse events 43 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Duration of exacerbation ‐ time to symptom recovery and lung function recovery 52 weeks · adults and children with chronic asthma
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether tripterygium polyglycoside changes improvement in disability grade Defined as achievement of a… compared with corticosteroids (very low certainty).
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
1 finding from 1 review
Intraocular inflammation measured by anterior chamber cell and flare 1 week · people who received phacoemulsification
1 finding from 1 review
Intraocular inflammation measured by proportion of participants with corneal edema 1 week · people who received phacoemulsification
Summary of findings for NSAIDs showed no clear difference in intraocular inflammation measured by proportion of participants with… compared with corticosteroids (low certainty).
1 finding from 1 review
Proportion of participants with best‐corrected visual acuity of 20/40 1 week · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with cystoid macular edema 1 week · people who received phacoemulsification
Summary of findings for NSAIDs may leads to lower proportion of participants with cystoid macular edema 1 week compared with corticosteroids (low certainty).
1 finding from 1 review
Time to cessation of treatment · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · patients with acute asthma
ICS showed no clear difference in hospital admission compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found